Riqviva 100 mg & 400 mg Concentrate for Solution for infusion
PDF Leaflet Revision Date: 15 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including metastatic colorectal, breast, lung, renal cell, cervical, and glioblastoma.
Dosage (summary)
5-15 mg/kg IV every 2-3 weeks depending on cancer type.
Special Populations
- Renal impairment
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment and for 6 months after.
Key Drug Interactions
- Sunitinib
- Platinum-based therapies
- Taxane-based therapies
Contraindications
- Hypersensitivity to bevacizumab
- Pregnancy
- Lactation
- Concomitant use with sunitinib
Common side effects
- Hypertension
- Fatigue
- Diarrhoea
- Abdominal pain
Counselling Points
- Use effective contraception during treatment
- Monitor for signs of hypertension
- Report any unusual bleeding or bruising
Serious warnings
- Gastrointestinal perforations
- Arterial thromboembolism
- Haemorrhage
- Wound healing complications
Important Disclaimer
The Riqviva 100 mg & 400 mg Concentrate for Solution for infusion professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
